- Home
- DLHC vs ABOS Comparison
DLHC vs ABOS Comparison
Compare DLHC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLHC
- ABOS
- Stock Information
- Founded
- DLHC 1969
- ABOS 1996
- Country
- DLHC United States
- ABOS United States
- Employees
- DLHC N/A
- ABOS 52
- Industry
- DLHC Business Services
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- DLHC Consumer Discretionary
- ABOS Health Care
- Exchange
- DLHC Nasdaq
- ABOS Nasdaq
- Market Cap
- DLHC 117.4M
- ABOS 113.6M
- IPO Year
- DLHC N/A
- ABOS 2021
- Fundamental
- Price
- DLHC $7.81
- ABOS $1.89
- Analyst Decision
- DLHC
- ABOS Strong Buy
- Analyst Count
- DLHC 0
- ABOS 3
- Target Price
- DLHC N/A
- ABOS $9.33
- AVG Volume (30 Days)
- DLHC 53.9K
- ABOS 379.9K
- Earning Date
- DLHC 01-29-2025
- ABOS 11-12-2024
- Dividend Yield
- DLHC N/A
- ABOS N/A
- EPS Growth
- DLHC 410.00
- ABOS N/A
- EPS
- DLHC 0.51
- ABOS N/A
- Revenue
- DLHC $395,937,000.00
- ABOS N/A
- Revenue This Year
- DLHC N/A
- ABOS N/A
- Revenue Next Year
- DLHC N/A
- ABOS N/A
- P/E Ratio
- DLHC $15.09
- ABOS N/A
- Revenue Growth
- DLHC 5.34
- ABOS N/A
- 52 Week Low
- DLHC $7.34
- ABOS $1.70
- 52 Week High
- DLHC $17.58
- ABOS $5.09
- Technical
- Relative Strength Index (RSI)
- DLHC 44.81
- ABOS 37.87
- Support Level
- DLHC $7.58
- ABOS $1.72
- Resistance Level
- DLHC $7.79
- ABOS $2.03
- Average True Range (ATR)
- DLHC 0.35
- ABOS 0.13
- MACD
- DLHC 0.02
- ABOS -0.01
- Stochastic Oscillator
- DLHC 42.73
- ABOS 32.20
About DLHC DLH Holdings Corp.
DLH Holdings Corp is a provider of technology-enabled business process outsourcing and program management solutions in the United States. The company offers services to several government agencies which include the Department of Veteran Affairs. It is engaged in public health, performance evaluation, and health operations to solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, analytics, cloud-based applications, and telehealth systems.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.